---
title: "Top Corvus Pharmaceuticals Insider Makes Bold New Bet on the Company’s Future"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289852660.md"
description: "Corvus Pharmaceuticals Director David Scott Moore purchased 21,700 shares for $250,201 on June 15, 2026, signaling confidence. Despite this insider buy and governance stability from the annual meeting, CRVS stock remains Neutral per TipRanks' AI due to weak financials, no revenue, and cash burn. The company has a $1B market cap with YTD performance of 54.94%."
datetime: "2026-06-16T02:14:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289852660.md)
  - [en](https://longbridge.com/en/news/289852660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289852660.md)
generator: "portal-rs"
---

# Top Corvus Pharmaceuticals Insider Makes Bold New Bet on the Company’s Future

New insider activity at Corvus Pharmaceuticals ( (CRVS) ) has taken place on June 15, 2026.

Director David Scott Moore has significantly increased his stake in Corvus Pharmaceuticals by purchasing 21,700 shares of the company’s stock in a recent transaction. This insider buy represents a cash outlay of $250,201, signaling a notable show of confidence from a member of Corvus Pharmaceuticals’ leadership team.

Corvus Pharmaceuticals’ stock saw limited price reaction over the last 24 hours as news centered on its 2026 Annual Meeting rather than earnings or major clinical results. Governance stability was reinforced by re-electing key board members, ratifying PricewaterhouseCoopers as auditor, and approving executive pay, which supported analyst confidence in leadership but did not materially change the risk from weak financials and cash burn.

**Spark’s Take on CRVS Stock**

According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and soft technicals (below key moving averages with negative MACD). Corporate events provide some offset via positive early clinical data and added capital-raising flexibility, but valuation support is limited due to ongoing losses and no dividend.

To see Spark’s full report on CRVS stock,  
 click here. 

**More about Corvus Pharmaceuticals**

**YTD Price Performance:** 54.94%

**Average Trading Volume:** 1,497,347

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $1B

### Related Stocks

- [CRVS.US](https://longbridge.com/en/quote/CRVS.US.md)

## Related News & Research

- [Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial](https://longbridge.com/en/news/297177476.md)
- [Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS](https://longbridge.com/en/news/295904031.md)
- [Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL](https://longbridge.com/en/news/297756537.md)
- [Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?](https://longbridge.com/en/news/297367016.md)
- [Headlands Technologies LLC Has $772,000 Stock Position in Agios Pharmaceuticals, Inc. $AGIO](https://longbridge.com/en/news/297751551.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**